Developing effective therapies for the treatment of Alzheimer's disease remains one of the key unmet medical needs facing society today. Worldwide, drug discovery research is poised to deliver the next generation of symptomatic as well as disease-modifying therapies to patients. This presentation will discuss approaches to target the amyloid β-peptide (Aβ) believed to play a central role in the pathogenesis of AD. This peptide is produced by the sequential proteolytic processing of the β-amyloid precursor protein (APP) by β-and γ-secretase. The novel membrane-bound aspartyl protease BACE1 (also called memapsin2 or Asp2) is now believed to be the major β-secretase activity and is considered an attractive therapeutic target for the treatment and prevention of AD. Similarly, the gamma secretase complex is responsible for the intra-membranous cleavage of APP. We will describe the identification of a potent and selective small molecule BACE1 inhibitors based on high-throughput screening of the Wyeth compound library. Optimization of hits by medicinal chemistry resulted in lead compounds with nanomolar potency in inhibiting BACE1-mediated cleavage of a peptide substrate. These compounds also display selectively against BACE2, Cathepsin D, and pepsin. Furthermore, these hits lowered production of Aβ secreted by APP-expressing cell lines, primary neurons, and in brain slices transfected with either wild type APP, or APP containing one or human mutations linked to AD. In addition, oral single acute or subchronic administration of these compounds to Tg2576 mice resulted in a significant decrease in Aβ 40 in plasma and Aβ 40/42 in brain. Chronic dosing experiments indicated that these compounds also have efficacy in decreasing the plaque load in Tg2576 animals. The efficacy of these BACE inhibitors was further examined in behavioral assays. Using a contextual fear-conditioning model of memory, BACE-1 inhibitors were shown to reverse cognitive deficits exhibited by the Tg2576 model of AD. Overall, these data represent one of the first descriptions of a potent, selective, and orally active small molecule BACE1 inhibitor that will contribute toward our understanding of APP processing, and represents an exciting candidate for a disease-modifying AD therapeutic.
Discovery & Early Validation of Peripheral Biomarkers of Alzheimer's Disease
Paul Cutler GSK, UK Peripheral biomarkers of Alzheimer's disease (AD) could have important clinical utility, providing increased certainty in the positive diagnosis of AD, particularly in the early phase of disease progression where a patient with mild cognitive impairment may have either incipient AD or have a benign form of mild cognitive impairment. Biomarkers may also provide a means of monitoring drug efficacy. In order to identify such biomarkers, an extensive and well-characterized cohort of AD patients and matched controls was assembled, facilitating genetic and genomicanalysis. A number of plasma samples from Alzheimer patients were subjected to analysis by both gel-based and non-gel-based proteomics, leading to the identification of a number of proteins showing a significant statistical association with the disease. These were also compared to proteins observed differentially regulated in a mouse model of amyloidosis (TAS TPM mouse). Using specific assays, a number of these proteins have undergone initial validation, resulting in a number of encouraging potential peripheral biomarkers of AD and the identification of at least two biomarkers, which have Menthol is commonly used in the food and flavor industry for its cooling properties, but its use is limited by other unwanted sensory properties as well as the short duration of cooling that is elicited by menthol. In vivo, menthol stimulates TRPM8, which is a ligand-gated nonselective, cation channel that is robustly activated by cool temperatures and other chemical stimuli such as icilin. We created a stable mammalian cell line expressing the human TRPM8 receptor and developed an assay to evaluate TRPM8-dependent Ca2+ entry using Ca2+-sensitive fluorescent dyes. This assay was used in an HTS campaign with a high-diversity library of small molecules, resulting in the identification of hit compounds that stimulated TRPM8-mediated Ca2+ influx. Potent and selective TRPM8 agonists derived from the screen were used in vivo to assess oral cooling efficacy in human subjects. When tested in common consumer applications such as toothpaste, one analog elicited cooling sensations for up to 2 hours after brushing compared to only 15 minutes for the menthol reference. This analog was selected as a development candidate, evaluated in safety studies, and determined to be Generally Recognized as Safe (GRAS) by an expert panel of the Flavor and Extract and Manufacturers Association. This determination allows for its use in a variety of consumer products in the USA and facilitates acceptance throughout the world. This represents one of the first commercial examples using pharma-type screening approaches to identify high-impact flavoring materials that are active against the thermoTRP family of receptors.
proprietary flavor molecules. Dr. Slack was hired in 2000 as a Research Scientist to form this group following the 1999 discovery of the first taste receptor genes. Currently, their focus is to use assays for both GPCRs and TRP channels to discover novel molecules that allow them to modulate taste perception, including sweet enhancement, bitter masking, and novel sensates such as cooling or pungency.

SESSION II
A Chemical Approach to Stem Cell Biology
Sheng Ding-Plenary Speaker The Scripps Research Institute, USA Recent advances in stem cell biology may make possible new approaches for the treatment of a number of diseases. A better understanding of the molecular mechanisms that control stem cell fates as well as an improved ability to manipulate them are required. Toward these goals, we have developed and implemented chemical and functional genomic tools, including highthroughput cell-based phenotypic screens of arrayed chemical, cDNA and RNAi libraries, genomic and proteomic profiling of homogenous undifferentiated/self-renewing or selectively differentiated cell populations under chemically defined conditions, and in-depth biochemical and functional assays in vitro and in vivo, to identify and further characterize small molecules and genes that can control stem cell fate in various systems. This talk will provide specific examples of stem cell discovery efforts in my lab that have advanced our ability and understanding toward controlling embryonic stem cell fate.
Human Hepatocytes from Various Human Stem Cell Sources for Use in Drug Discovery
Mark Johnston ADMET Technologies, USA Pharmaceutical companies lack a consistent supply of primary human hepatocytes for drug-discovery purposes and are forced to use suboptimal cell-based models including (I) animal hepatocytes which are not predictive of findings in humans, (II) transformed cell lines which do not contain the full complement of human liver−specific function, and (III) primary human hepatocytes which are limited in supply and are highly variable in quality. Studies with human livers and human umbilical cords have found defined subpopulations of stem/progenitor cells capable of extensive proliferation as well as differentiation into various cell types, including hepatocytes. Our goal is to produce fully characterized, fully functional human hepatocytes to address the existing gap in drug discovery in order to (1) increase screening capacity with a large supply of human physiologically relevant hepatocytes to improve candidate selection; (2) create a bank of genetically diverse hepatocytes to (a) eliminate/reduce adverse events during clinical trials, (b) assess genotype specific toxicity, (c) understand the mechanism of action for better/safer drugs, and (d) have the ability to use the same cell across the drug discovery spectrum throughout the drug development lifespan; (3) reduce reagent costs; and (4) allow for new assays including longer term chronic toxicity assays and drug-drug interaction studies. This presentation will describe our efforts to manufacture nontransformed human hepatocytes from various human stem cell sources including an assessment of liver cell function through Cytochrome P450 activity, urea, albumin production, cell viability, cell number, cell growth, and scale-up production techniques.
Stem & Primary Cells Containing a Calcium-Sensitive Reporter Gene: Validation and Use in HTS
Sabrina Corazza Axxam, Italy
Transformed cell lines have been the mainstay of assay development since the beginning of HTS. The use of recombinantly expressed targets is well established and more convenient than the use of primary or stem cells in HTS but may suffer undefined changes in cell physiology occasioned by high expression, missing interaction partners, or toxic effects of the transfected target. Primary and stem cells are far less likely to introduce artifacts of this nature and thus represent a more physiological system. One of the first challenges in using primary or stem cells in HTS is devising a reporter system to allow sensitive and accurate read-out. To overcome this challenge, we stably expressed Photina ® , a calcium-sensitive photoprotein, in a mouse embryonic stem cell (mES) line and a mouse embryonic carcinoma p19 cell line (mEC), as a reporter gene. The mES-reporter cell line was used to generate a transgenic mouse expressing the Photina, reporter gene driven by a ubiquitous promoter, which led to expression of the reporter in most tissues. The outcome of this work was the generation of a comprehensive platform of primary cells and stem cells derived primary cells stably expressing Photina, which can be used for miniaturized screening processes in 384 MTP. The mES and mEC-reporter cell lines are particularly well suited to studying the pharmacological modulation of target genes that use calcium as a second messenger. Primary cells derived from the transgenic animal tissues can be isolated, cultivated, and used directly for functional experiments of target-induced intracellular calcium movements. The availability of Photina, intrinsically expressed in the primary cells, allows their direct use in assays within hours of their isolation. Data will show the validation of these three different cell sources in a screening format (384) using both luminescence and fluorescent read-outs. Attention will be focused particularly on the strengths and weaknesses of such systems in HTS, and a specific example using stem cells differentiated into neurons will be presented. 
Sabrina Corazza received a degree in 1993 in
Stem Cells: From Assay to Screen
Donna McLaren Stem Cell Sciences Ltd, UK
The medicines of tomorrow are being developed based upon the high-throughput drug-discovery screens of today, and stem cells are emerging as groundbreaking resources for cell-based screens. While the sheer complexity of the stem cell culture microenvironment has previously hampered the faithful propagation of stem cells at scale, novel culture methodologies have now made automation feasible and therefore presented stem cells as realistic screening tools. There is utility for stem cells both as entities in themselves for regenerative medicine screening applications and as a raw material for the generation of specialized differentiated cell populations. Several mouse and human stem cell lines have been automated to culture at scale, and current priorities are to generate robust cell-based assay data, which will illustrate the potential for screening applications. The challenge is to devise simple assays using unique cell populations and maintain the integrity of the two; overcoming this challenge has already made stem cell−based drug discovery screening a reality. Stem cell−based screens will not only progress ongoing drug development programs but will also be an essential building block of the exciting future of stem cell−based therapeutic programs. Centralized high-throughput screening (HTS) groups and other lead-identification platforms (e.g., fragment-based screening) were established at most of the major pharmaceutical companies over a decade ago. These new technology platforms were developed with the intent of revolutionizing the way to find new drugs. A number of articles have reported that the drug industry's big push into technologies such as screening (along with combinatorial chemistry & other hyped technologies) was falling short of expectations. However, because the long cycle times of drug discovery is poorly understood in the public sector, the impact of lead identification has yet to be fully appreciated as a drug-discovery engine. This presentation will focus on the contributions and impact of the Abbott lead identification teams (including "lessons learned") from over a decade of NMR, affinity, fragment-based, ultra-high-throughput, and traditional screening, as well as highlight future initiatives/technologies/ideas being implemented to enhance and improve the drug-discovery process. (Lead Discovery team) The use of protein sensors to detect biological processes is emerging as an exciting field of research with potential application to ultra high-throughput screening (uHTS). A new biosensor has been created that incorporates the cAMP-binding domain of PKA into a mutant firefly luciferase enzyme such that luminescence is emitted in proportion to intracellular cAMP concentration. The kinetics of cAMP modulation can be evaluated using this live cell assay technology, offering significant advantages over end-point assays in which the cells are lysed. This cAMP biosensor has been stably expressed in human embryonic kidney (HEK) cells. Here we report the evaluation of this biosensor upon stimulation of endogenous receptors on HEK cells. This system has been used to evaluate both agonists and antagonists of GPCRs in 384-well, 1536-well, and 3456-well assay plate formats, demonstrating the feasibility of this assay technology for miniaturized uHTS. Thus, this biosensor provides a valuable option in the detection of transient second messengers like cAMP as a measure of cell signaling. GPCRs represent one of the most successfully mined drug target families. However, a point of diminishing returns has been reached as the ligands and function of arguably the most challenging set of GPCRs, the orphans, remain to be discovered. Orphan GPCRs represent a major challenge in that without tool agonists to probe function in vivo, it is difficult to assess their role in normal and disease physiology. In addition, discovering agonists, whether natural ligands or synthetic tools, is challenging from the perspective of assay development. At GNF we have designed an experimental system aimed toward identifying agonist tools from large, diverse libraries of natural and synthetic origin against panels of orphan GPCRs simultaneously in multiple assay formats. To accomplish this large-scale fishing expedition rapidly and cost-effectively, we have built a robotic platform with the ability to automatically profile activities of >100,000 molecules against panels of >100 cellular assays in 1536-well plate format in a single experiment. The system was used in conjunction with a variety of key GPCR assay formats suited to de-orphaning to profile 100,000 molecules against 30 orphan GPCRs in a 2-week experiment. This talk will describe the Automated Cellular Profiling system (ACP), now in its second generation, the utility and implementation of various de-orphaning assay formats including DiscoverX's PathHunter, PerkinElmer's Aequorin, and PerkinElmer's LumiLux technologies on the ACP, and the results of this first-of-kind large scale GPCR agonist tool finding experiment. Diego, CA. From 1989 to 1992 
Donna McLaren is a Research
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Second-Harmonic Generation (SHG) for Identification of Allosteric and Conformation-Specific Compounds
Joshua S. Salafsky Biodesy, LLC, USA Second-harmonic generation (SHG) is a nonlinear optical technique that is well known in physics and chemistry for its ability to detect molecules on surfaces and quantitatively determine their average orientation. By labeling biomolecules with an SH-active dye probe, any biomolecule can be detected on a surface by SHG, opening up a number of applications for drug discovery and new avenues for basic research. Labeled biomolecules placed on a surface produce a baseline SHG signal: conformational change, induced by a drug or a ligand, alters the orientation of the probe and the measured SH intensity. SHG requires only a tiny amount of sample (10^5-10^6 biomolecules in a focal spot size of 30 microns), and it is directly sensitive to structure in real time. For basic research, SHG is a viable complement to NMR for detecting a biomolecule's conformational change. In systems in which biomolecules are oriented on a surface, SHG could be used to measure the angular change of a probe and thus provide a "motion picture" of conformational change. As a tool for drug discovery, it is a screening platform for identifying allosteric or conformation-specific compounds, without the need for a crystal structure. Results with a variety of protein targets will be presented, including an integrin receptor, amyloids, and a kinase. Importantly, the technique is sensitive enough to distinguish between different conformations, even when the protein is labeled non-site-specifically. Because SHG can be used for fragment-based drug discovery or scaled up for high-throughput drug screening, it should play an important role in identifying new compounds that induce or stabilize specific target conformations. 
Joshua
SESSION IV
Discovery of NVP-BEZ235-A Dual PI3K/mTOR Inhibitor for Targeted Cancer Treatment
Carlos Garcia-Echeverria-Plenary Speaker Novartis Institutes for Biomedical Research, Switzerland
The phosphatidylinositol-3-kinase/protein kinase B (PI3K/PKB) signaling pathway-also known as the survival or anti-apoptotic pathway-plays an important role in controlling cell growth, proliferation, and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in human cancers and its potential biological effects (e.g., competitive growth advantage, evasion from apoptosis, and therapy resistance) has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents in oncology. Following a structure-based design strategy, we have identified a clinical candidate-NVP-BEZ235-that exhibits potent antiproliferative activity against a broad panel of tumor cell lines (GI50 = 172-7 nM) by specifically blocking the biological function of PI3K signaling components (e.g., IC50 = 10 ± 1 nM, p-PKB inhibition in U87MG cells). The activity of this dual PI3K/mTOR ATP-competitive inhibitor in cellular settings translates well in the in vivo models of human cancer. Thus, the compound was well tolerated and displayed disease status or tumor regression when administered orally-25 to 50 mg/kg/day-and enhanced the efficacy of other anticancer agents when used in in vivo combination studies. Ex-vivo PK/PD analyses of tumor tissues showed a time-dependent correlation between compound concentration and PI3K/PKB pathway inhibition. Of special concern for an anti-PI3K therapy is insulin resistance. Under physiological conditions, the effects of insulin on metabolism are mediated through the PI3K/PKB pathway and anti-PI3K agents are therefore likely to perturb glucose metabolism and cause insulin resistance if the pathway is blocked in selected tissues. In this context, it has been shown that compounds targeting p110a can block the acute effects of insulin treatment in vivo, whereas a p110b inhibitor has no effect. Contrary to other modulators of the PI3K/PKB pathway and upon comparison with the mean glucose level of the control animals, no elevated blood glucose levels were observed in the animals treated with NVP-BEZ235 after in vivo efficacy experiments in mice or rats. Moreover, no effect on insulin or glucose levels was reported for NVP-BEZ235 at efficacious doses in a 13-week rat tox study. Phase I clinical studies with this compound were initiated in December 2006. Many tumors are defective in the tumor suppressor p53 and therefore lack a functional G1 checkpoint. In these tumors, however, the S/G2 checkpoints remain intact and, in response to DNA damage, arrest cell cycle progression to enable DNA repair. Checkpoint kinase 1 (Chk1) is a key element in the DNA damage response pathway and plays a crucial role in the S/G2 phase checkpoints. Inhibiting Chk1 represents a therapeutic strategy for overriding the tumor cell's last checkpoint defense against the lethal damage induced by DNA-directed chemotherapeutic agents. Inhibiting Chk1 may define a molecular-based strategy to selectively target tumors with intrinsic checkpoint defects while minimizing toxicity in normal cells. PF-00477736 is a potent, selective ATP-competitive Chk1 inhibitor from the diazapinoindolone series that inhibits Chk1 with a Ki = 0.49 nM. Checkpoint abrogating activity was demonstrated by an increase in phospho-histone H3 and increased sub-G1 population as determined by flow cytometry. PF-00477736 abrogates cell cycle arrest induced by DNA damage and enhances cytotoxicity of clinically important chemotherapeutic agents, including gemcitabine, irinotecan, and carboplatin. The addition of PF-00477736 to gemcitabinetreated cells decreased Chk1 and CDK1 phosphorylation, increased the presence of the hyperphosphorylated form of Cdc25C, and increased cyclin B, phos-gamma-H2AX, and apoptosis, all of which provide evidence of checkpoint abrogation, cell cycle progression through metaphase of mitosis, increased DNA damage, and cytotoxicity. In xenografts, PF-00477736 enhanced the antitumor activity of gemcitabine and irinotecan. PF-00477736 combinations were well tolerated with no exacerbation of side effects commonly associated with cytotoxic agents. The development of strategies to monitor the molecular and cellular response to novel agents that target the cell cycle is vital to provide proof of mechanism and biological activity of these compounds. Functional imaging with 18F-fluorine-L-thymidine (FLT) revealed a significant increase, or flare, in uptake of FLT in xenografts treated with gemcitabine. The Hedgehog, PI3K/Akt, BMP, TGFbeta, FGF, WNT, and Notch signaling pathways are crucial to a variety of processes, such as embryogenesis, maintenance of adult tissue homeostasis, tissue repair after chronic inflammation, and carcinogenesis. The misregulation of these pathways has been detected in numerous human malignancies. The combined activities of these pathways impact stem cell fate and offer new potential targets for therapeutic intervention. Here we show that with a properly focused and integrated (chemistry + biology) strategy it is possible to efficiently interrogate signaling pathways with manageable (~10K-15K) small molecule collection. First, we started with a precisely designed and selected "Focused Diversity" screening collection, consisting of targeted and annotated sets as well as components of fragment-based, peptidomimetics, and natural-like libraries. With this diverse collection of focused sets we are able to identify new chemical modulators of multiple targets in the pathway, after just minimal screening and SAR expansion. That combined with a precisely selected set of biochemical and functional assays as well as appropriate in vitro and in vivo pharmacology allowed us to quickly move from hits to proofof-concept in animal models. This very effective strategy will be illustrated with the Hedgehog Signaling Pathway. VHR is a dual-specific phosphatase and a negative regulator of the Erk and Jnk mitogen-activated protein kinase pathways. Loss of VHR causes cell cycle arrest in HeLa cervix carcinoma cells, suggesting that VHR inhibition may be a useful approach to halt the growth of cancer cells without detrimental effects on normal cells. Moreover, VHR was found to be upregulated in several cervix cancer cell lines as well as in squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Here we report the development of novel multidentate small molecule inhibitors of VHR that inhibit its enzymatic activity at nanomolar concentrations in vitro and are active at low micromolar concentrations on several cell lines and primary cells. High-throughput chemical library screening was used to identify hits that were further prioritized in profiling experiments. Structure-based methods were applied in the search for analogs with improved potency and selectivity, resulting in multidentate inhibitors, the binding mode of which was confirmed by x-ray crystallography. Finally, evaluation of the inhibitors in several cell-based assays confirmed their ability to penetrate cell membranes as well as their selectivity in targeting VHR. The inhibitors were able to hold the proliferation of cervix cancer cells but didn't show antiproliferative or cytotoxic effects on normal keratinocytes. These compounds may be a starting point for developing drugs for the treatment of cervical cancer. In the post-genomic era of biomedical research, understanding the functionality of molecules at the cellular and subcellular level in living systems will become predominant. In this era we must move beyond static "snapshots" of the cellular state to an understanding of the biology of cells over time and in 3-dimensional-space. Within the cellular environment it is expected that we will be able to study the expression, the functional role(s), and interactions of multiple unique molecules concurrently. Furthermore, it will be desirable to determine the effects of these molecules on cell development, organization, and fate over extended periods of time. To perform these types of studies, it is necessary to develop new methodologies that will allow multiparametric analysis of cells while maintaining their functional viability. In the past this goal would have been extraordinarily difficult to achieve. However, developments in optical, computational, and dye technology have empowered modern microscopists to undertake these previously forbidding tasks. The seminar given will focus on the technical advantages and limitations of novel optical imaging tools and will discuss the expectations and limitations within the context of current scientific problems in Immunology specifically focusing on imaging cell-cell communication between dendritic cells at high resolution. This presentation will also consider some of the primary limitations of current computing, storage, and image processing which will become increasingly pressing over the next 10 years as high-speed multimode methodologies become mainstream. 
Carlos Garcia-Echeverria
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Challenges in High-Content Imaging of Complex Primary Co-Cultures of Cortex and Striatum for Neurodegenerative Diseases
Oscar Joseph Trask Duke University, USA While conventional cell-based screening systems are generally limited to the use of homogeneous cell lines, high-content imaging technologies promise the ability to analyze mixed, co-culture systems that recapitulate more fully the complex milieu of brain tissue by supporting the interconnected growth of multiple neuronal and glial cell types within the same culture wells. Multiple challenges for biological validation arise from the complexity and heterogeneity of such mixed neural cultures, and for the use of automated fluorescence microscopy to quantify altered morphological and functional features of the cell species of interest within the mixed background of these cultures. We describe here the development and use of a primary neuronal co-culture system that includes neurons and glia isolated from rat brain cortex and striatum to advance small molecule drug-discovery screening efforts in Huntington's disease. In this co-culture system, cortical and striatal neurons were selectively transfected with CFP or YFP, respectively, together with either control or mutant huntingtin (htt) gene constructs, using electroportation and cultured on a glial support matrix. The neurodegeneration of striatal neurons caused by mutant htt gene transfection, and its amelioration of survival by drug candidates, were quantified using high-content imaging and analysis over the course of several days following transfection. We will discuss the approaches and challenges involved in developing, validating, and screening compounds using this neuronal co-culture screening platform. 
Oscar Joseph (Joe) Trask is currently Head of Cellular
Genome-Wide Multi-Parametric Endocytosis Screen Reveals Challenges and Limitations of Current siRNA Technology
Eberhard Krausz Max Planck Institute, Germany
Endocytosis is a fundamental biological process with a number of links to human diseases. A genome-wide siRNA screen has been implemented to identify novel regulators and components of endocytic pathways. A multi-parametric threecolor assay has been developed and our homemade "Motion Tracker II" image analysis solution pushed toward extracting over 60 different parameters. We screened up to 7 siRNAs per target of two siRNA libraries and compared those to a library of endoribonuclease-prepared esiRNAs. Screening data will be presented. The performance of independent siRNAs designed to target the same gene across the multiple parameters shows very sensitively the degree of specificity and extent of off-target effects. Pitfalls of siRNA technology in correlation to truly multi-parametric assays and putative impact on screening and hit verification strategies will be discussed. 
Eberhard Krausz was head of the High-Throughput Technology Development Studio (TDS), the High-Content Screening Labs of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in
Miniaturized High-Content Assays of Rare Cancer Side Population Cells on Planar Arrays
Kwong Joo Leck Institute of Bioengineering & Nanotechnology, Singapore Assay miniaturization reduces sample and reagent consumption, accelerates assay kinetics, and lowers assay cost. Despite these advantages, there are many challenges in miniaturizing "wash-based" assays performed on a multi-well plate due to differential carry-over and non-uniformity of rinsing across different wells. We have developed Drop Assays on Planar Arrays (DAPA), a simple and cost-effective method that enables the convenient miniaturization of a wide range of biochemical and cell-based assays typically performed on a multi-well plate. The method, which is easily amenable to automation, is capable of miniaturizing conventional bioassays down to the nanoliter scale. We have applied this method for highcontent assays of rare cancer side population cells. Cancer side population cells are identified based on their ability to efflux the vital dHoechst 33342. These cells typically constitute less than 2% of a cancer cell population and they have been demonstrated in previous studies to possess stem cell-like characteristics and greater resistance to radiotherapy and various chemotherapeutic agents. It is challenging to perform screening assays on these cells due to the large number of cells required. Using DAPA, we can reduce the number of cells needed per data point by at least 10 times as a typical DAPA cell immunofluorescence staining assay at 2-3 uL scale requires less than 200 cells for each data point. The antibody incubation step is usually the most time-consuming step in cell immunofluorescence staining assays. As a result of the shorter diffusion distances and greater encounter frequencies between binding partners in a smaller assay volume, DAPA also produces significant savings in assay time. For example, a 1-hour antibody incubation step can be reduced to just 10 minutes. The DAPA technology expected to enable high-content assays with rare and expensive cells that have previously not been practical to perform and significantly lower the cost of drug discovery. 
Kwong-Joo Leck is currently the Chief Scientific
Incorporating Protein-Protein Interaction Biosensors into Cellular Models Characterized with Cellular Systems Biology Profiling
Kenneth Giuliano Cellumen, Inc., USA Certain targets are not compatible with cell-based screening either because their expression is toxic or because methods to manipulate and measure their activity are not available. Positional-based protein-protein interaction biosensors (PPIBs) and inducible protein systems enable drug discovery for many such previously intractable targets. PPIBs report on reversible protein-protein interactions in living cells through dynamic changes in their cellular localization. The design of PPIBs enables integration into cellular models of disease in which expression of key targets is regulated with inducible promoter systems. To demonstrate, a cellular model of cancer was generated that included inducible p53 expression and PPIBs to detect the interaction of several domains of p53 and HDM2. An optimized PPIB was incorporated into an adenovirus delivery system, and the effects of both the adenovirus and the PPIB on multiple biomarkers were profiled. Adenoviral delivery of a control protein showed that the delivery system itself had minimal effects on cell cycle regulation, nuclear size, and chromatin condensation at several time points and MOIs. Adenoviral expression of the p53-HDM2 PPIB was assessed with the same biomarkers, and it was determined that adverse effects were minimal at early time points. The adenoviral PPIB was incorporated in to a Cellular Systems Biology (CSB) profiling assay for disruptors of the p53-HDM2 interaction along with 17 other biomarkers, including measures of cell cycle regulation, nuclear morphology, DNA damage response, metabolism, cytoskeletal integrity, stress kinase, and transcription factor activation. CSB profiling visualization tools, including heat maps with hierarchical clustering, distribution maps, and cell maps, were used to simultaneously identify hits and profile their advantageous and nondesirable properties in the context of cellular systemic function. Data will be presented to confirm that cellular models of disease incorporating PPIBs, inducible proteins, and CSB profiling enables identification of hits for difficult targets. 
Ken Giuliano currently serves as Principal
SESSION VI
HTS & Chemical Genomics in Academia: Opportunity and Challenge
Christopher Austin-Plenary Speaker National Institutes of Health, USA
The sequencing of the human genome provided both enormous opportunities for biomedical research and daunting scientific, organizational, and funding challenges for both public and private sector research. The broad realization that small molecule compounds can be unique physiological probes of gene/protein function and the desire of academic researchers to engage in more explicitly translational research have led to a dramatic increase in public sector HTS. In most cases, academic researchers focus on targets and diseases that are outside the traditional purview of the biopharma, and may lead to "de-risking" of novel targets and their subsequent adoption by drug development organizations. The NIH Molecular Libraries Initiative (MLI), begun in 2003, represented an ambitious multifaceted attempt to enable public sector researchers to use small molecules in their research, whether as tools to perturb genes and pathways or as starting points for the development of new therapeutics for human disease. A landmark feature of this initiative was the unencumbered deposition of all MLI data into a new public database, thus establishing a firmly precompetitive space for small molecule research. While this and similar efforts are now productive, they have highlighted the need for additional training opportunities in pharmacology, chemistry, and cheminformatics, and raised issues about the role of downstream drug development in the public sector. This presentation will discuss these developments, illustrated by projects from the NCGC and other centers of the MLI. In the two years since becoming fully operational, the Penn Center for Molecular Discovery (PCMD) has completed more than 20 HTS campaigns and several hit-to-lead programs. Setting up an HTS lab from scratch presented challenges, but also the opportunity to design and build a state-of-the-art screening and informatics infrastructure. Two parallel screening lines are in operation. One of these is served by a linear track robot, pintool transfer for 1536-well HTS, and tip-based liquid handling for compound reformatting and dose-response testing. The second HTS line integrates liquid handling in a sterile tissue culture hood with an enclosed screening deck for cell-based assays. Acoustic dispense and imaging instruments are available to enable microarray screening and high-content cell-based assays. A library of over 700,000 compounds obtained from Biofocus-DPI and other sources is stored on site in 384-and 1536-well plates. We have designed flexible systems and protocols that allow us to screen in formats ranging from 96-to 1536-well plates as well as microarrays. Assays vary in complexity from simple biochemical screens to complex cell-based and whole-organism assays. Projects focus on blood systems biology and a variety of bacterial, viral, fungal, and parasitic pathogens that are of global concern. Examples will be presented from our work leading to the development of novel chemical probes against fungal biofilms, TB cell wall biosynthesis, malarial parasite invasion of red blood cells, viral entry into host cells, and blood systems pathways. As part of the Molecular Libraries Screening Center Network, the PCMD has access to a huge breadth of biological and chemical research in the US and abroad, providing enormous opportunity to explore novel areas of chemical biology and to present the results of these endeavors to the wider drug discovery community. The Broad Institute small-molecule screening facility has been in operation for over 10 years, and its highly successful Investigator-Initiated Screening Program has enabled small-molecule screening projects for more than 140 different research groups from throughout the US and abroad. The facility is part of a rich community composed of scientists from a wide range of disciplines (chemistry, biology, computational science, software, and automation engineering), all working cooperatively toward the goals of probe and lead discovery in a systematic and thorough manner. The diversity-oriented synthesis (DOS) platform harnesses the power of split-and-pool synthesis to build-through efficient synthetic pathways-large collections of diverse small molecules having structural complexity rivaling naturally occurring small molecules, and having chemical handles that enable systematic optimization or modification. The screening facility uses custom automation to manage and screen the Broad Institute small-molecule collection (including DOS libraries) and performs both target-based biochemical screens and cell-based phenotypic screens, using novel screening approaches with relevance to several disease areas, including psychiatric disease, cancer, infectious disease, and metabolic disease. The informatics platform manages data collection and integration throughout the end-to-end process from chemical synthesis through screening and data analysis. All chemistry and screening data are deposited in an open-source data repository and analysis environment, ChemBank, and are available to the entire research community within a year of generation. This presentation will describe how researchers can take advantage of these capabilities and will highlight how these activities may impact modern drug discovery. Carbone Comprehensive Cancer Center. Since its introduction, the facility has become an active and essential core facility facilitating the research and drug discovery activities involving small molecules for the UW campus and several local companies. The facility possesses over 85,000 unique small molecules and natural products, including compounds that have been collected from the UW campus as part of our Discovery Library Project. The facility possesses automation and infrastructure for high-throughput and ultra high-throughput screening and detection, including dedicated space and equipment for screening at biosafety level 2. The facility utilizes Activity Base (IDBS, Inc), Spotfire, Pipeline Pilot, and other chemical and biological informatics tools to store and analyze all data generated by the facility. In addition to providing access to high-throughput screening, the facility offers high-throughput, multiplexed mechanism of action and cytotoxicity assays in cancer cell lines on lead screening compounds or chemicals provided by investigators. This service greatly facilitates the drug-discovery efforts on campus including the UW National Cooperative Drug Discovery Group. Assistance in lead expansion is performed by our two staff chemists in our newly established Medicinal Chemistry Core Facility. The experienced staff work with investigators at every step of the process and serve as project managers for each new study initiated at the facility. The facility has become an essential resource for the UW campus and provides valuable technical education to users and staff of the facility. This talk will highlight our unique experiences, advantages, and disadvantages of highthroughput screening in an academic setting.
Christopher Austin is Director of the NIH Chemical Genomics Center (NCGC), and Senior Advisor to the Director for Translational Research at the National Human Genome Research Institute (NHGRI
Andrew Napper is Director of High-Throughput Screening at the Penn Center for Molecular Discovery, one of ten centers in the Molecular Libraries Screening Center Network (MLSCN
Nicola (Nicky) Tolliday
Overcoming the Challenges of Drug Discovery in Academia: Filling the Gap with Examples of Drug Discovery Projects at Harvard
Marcie Glicksman Harvard NeuroDiscovery Center, USA
The model of drug discovery is changing. As the pharmaceutical industry looks for later stage projects to fill their pipeline, there is a gap that has formed between basic research and the identification of drug candidates. The Laboratory for Drug Discovery at the Harvard NeuroDiscovery Center is a model for how academia can apply its research findings to drug discovery especially in diseases and approaches that are not commonly found in the pharmaceutical industry. Our primary mission is to identify chemical agents from our library of 150,000 compounds that can serve as lead structures for the development of therapeutics for neurodegenerative diseases. This includes five diseases: Alzheimer's, Parkinson's, Huntington's diseases, amyotrophic lateral sclerosis, and multiple sclerosis. We have more recently applied our same model to non-CNS disease areas and formed the Partners Center for Drug Discovery. We are a group of 18 people, many of whom have come from industry that covers biology, medicinal chemistry, informatics, and computational chemistry. We operate in a collaborative mode with each of approximately 25 projects in partnership with a research lab at a university. Our funding sources include grants, philanthropy, and industry collaborations. Unexpectedly, the vendor community is a rich source for collaboration that allows the academic community access to new technologies. Details will be provided on the essential elements and challenges for our academic drug discovery center including examples of current projects. 
Marcie Glicksman is Senior
SESSION VII
A Complete Process for Qualitative and Quantitative Library Analysis
Kenneth Lewis OpAns LLC, USA In pharmaceutical R&D, three questions are consistently asked: 1) Is the expected compound present in the sample? 2) How pure is the sample? 3) How much is in the sample? These questions are particularly relevant early in discovery when hundreds of thousands of samples are being assayed and little is known about each sample. Early approaches to answer these questions for screening libraries usually sacrificed quality to achieve the necessary throughput at an affordable cost. The information generated from these efforts, although useful, was often insufficient to answer the three critical questions. Therefore, samples of interest were often reanalyzed by a higher quality method. This additional analysis required additional resources and delayed the decisionmaking process. This presentation will describe our approach of developing optimized instrumentation consisting of sub 3um particle HPLC, Diode Array UV detection, Evaporative Light Scattering Detection, Chemiluminescent Nitrogen Detection, and Mass Spectrometric Detection to provide the data necessary to answer these three questions. To efficiently translate the data from this system into results, we developed a software platform called Analytical Studio. Combining the optimized instrumentation with automated data analysis has enabled our lab to efficiently analyze hundreds of thousands of samples with an emphasis on the details necessary to get the correct answer for every sample. Through the use of examples, the whole process will be demonstrated. Particular focus will be given to three areas: 1. The requirement for generating quality analytical data; 2. The necessity of accurately interpreting the data; and 3. Using the results to drive decisions. The Lead Optimization (LO) process has become a critical engine in identifying novel chemical entities for pharmaceutical drug discovery. The pace of this operation is strictly tied to the rate at which newly synthesized chemistry submissions and cherrypicked requests can be processed to generate biologically relevant results. Thus, to shorten this cycle, the ability to provide assayready compound plates becomes increasingly important. To efficiently support this operation, we have designed and implemented a fully integrated local compound storage and liquid handling automated system amenable to the specialized needs of LO. This system was constructed in collaboration with REMP-Tecan (Oberdiessbach, Switzerland) and High Resolution Engineering (HRE, Woburn, MA), and is based on a novel approach that allows automated dynamic generation of assay ready plates from direct compound submissions. Key features include creation of the project-specific algorithms allowing for the calculation of number of plate copies, plate patterns, and predefined barcode generation. The process is based on the combination of direct automated compound ordering and liquid handling in one uninterrupted workflow. Compound processing methods can likewise be linked to the cherry-pick and control plating, thus producing a complete compound set for biological testing. We have also implemented a flexible cherry-pick approach, allowing the use of multiple strategies to select compounds for retesting. One of these strategies is to select compounds based on the minimal number of freeze/thaw cycles. We have evaluated standard commercial compound solutions, subjected to repeated cycles of freezing and thawing, to design the optimal workflow for efficient compound management. The combination of flexible integrated software and hardware with favorable storage conditions provides a basis for shortening the cycle time for generation of reliable biological data in support of lead optimization. 
Ken Lewis co-founded
Ilona Kariv currently heads the Automated Lead
COMDECOM: Predicting the Life Time of Compounds in DMSO Solution
Emrin Zitha-Bovens Specs, The Netherlands
In the COMDECOM project (COMpound DECOMposition), the compound stability of screening compounds in DMSO solution was monitored upon storage. The study was carried out in collaboration with seven pharmaceutical companies. A large database with stability data was developed, and from this database a predictive model is being developed. General screening compounds are often stored in DMSO solution. Unfortunately, pharmaceutical companies are currently faced with decomposition of a high percentage of their corporate compound file. The COMDECOM project was initiated to monitor the stability of about 15,000 compounds over a period of three years. Compound stability will be monitored in an accelerated thermal, hydrolytic, and oxidative decomposition program. In order to identify potentially unstable compounds, a predictive model will be developed from the generated data set. Project Outline: A diverse selection of 15,000 compounds from the Specs repository is stored in solution (in dry DMSO (~5% H20) and in DMSO/H20 (20% (v/v) H20)). The solutions are transferred into 96-shallow-well plates (Corning Costar) in several copies. The plates are sealed with aluminum foil and stored at different temperatures (50°C, 25°C, 4°C, -20°C). The solution composition is monitored at fixed time intervals (t = 0, 14, 35, 105 days, and 2.5 years) by LC/MS analysis. Predictive Model: From the generated dataset a predictive model is being built. The development of the algorithm is being carried out at the University of Erlangen-Nurnberg, in the group of Prof. J. Gasteiger, in collaboration with the Cheminformatics Departments of the members of the COMDECOM consortium. The aim is to build an algorithm that can flag compounds that are likely to decomposeinformation that we consider to be of utmost importance, for example, in the acquisition process and when evaluating screening results of library compounds. Over the last five years or so, the compound management teams of most major, and a number of smaller, pharmas have presented on how they deliver inventory to their customer base, and this inventory is, as a rule, composed of druggable molecules, and in a fixed delivery format. At Pfizer, the compound management teams in the Liquid Store Centre of Emphasis (LS CoE) and the Plate Provision group are working together and moving toward supplying a much more diverse collection of deliverables, not only in concentration and volume, but also substances ranging from low molecular weight "fragments" to RNA molecules. This presentation will describe what deliverables are available, how the Materials Management groups have determined what would be in demand, and how we worked through a number of issues and challenges with our key partners, such as Informatics, to ensure quality products are associated with quality data. In addition, this presentation will highlight how we manage and handle our compounds to maximize the integrity of the file using, for example, low volume dispensing to prepare assay ready plates. Finally, the authors will describe how replenishment and resupply of a multimillion compound collection is addressed in a proactive manner and on a global scale.
Partners
Terry Wood is currently head of the group, at Pfizer's research centre in the UK, responsible for the curation, storage, and delivery of the corporate compound collection using a number of automated and manual repositories. With degrees in chemistry and biology, Wood joined a new group at Pfizer in 1987 charged with exploring the emerging science of HighThroughput Screening. The requirement to produce quality data and maintain motivation of the lab team in those early days led him, together with global colleagues and vendors, to develop and apply a range of semiautomated solutions to the repetitive tasks required to screen a few thousand compounds each week. It was from challenges such as these that Wood's keen interest in automation and robotics developed.
SESSION VIII
Factors Influencing DDI Assessment from Early In Vitro Data
Jan Wahlstrom-Plenary Speaker Amgen, USA Early assessment of the potential for metabolism-based drugdrug interactions (DDI) is critical for designing safer therapeutics and reducing clinical attrition rates. Generally, four key experimental design features have the largest impact on the outcome of an in vitro DDI experiment: bioanalytical technique, reagent selection, reaction conditions, and experiment type. Within that paradigm, this presentation will focus on the potential impact of probe substrate selection, CYP reagent differences, and pharmacogenetics on the outcome of in vitro DDI studies. 
Jan Wahlstrom received his PhD in chemistry from
Luminogenic Cytochrome P450 Assays: Comparing Inhibition and Induction Outcomes to Outcomes from Conventional Methods
James Cali Promega Corp., USA Assays that measure inhibition and induction of drug-metabolizing cytochrome P450s (CYPs) are critical to drug discovery and development. As CYP assays are moved to earlier points in the discovery/development timeline, the numbers of test compounds increases as does the need for predictive high-throughput assays that are safe, sensitive, cost-effective, and simple to perform. To overcome limitations of conventional CYP assays concerning one or more of these criteria, luminogenic CYP enzyme assays were developed. The assays use probe CYP substrates that are inactive luciferin derivatives that vary in selectivity for CYP enzymes with variations at two derivatized positions. CYPs convert the substrates to an active luciferin that is detected in a second reaction with luciferase that generates light in proportion to the amount of CYP enzyme activity. While this method is a rapid, simple-to-perform high-throughput approach, it is important to determine its value for predicting clinically relevant CYP interactions. This has been considered by comparing assay outcomes to outcomes from conventional methods. For example, IC50s measured by the luminogenic method are typically found to correlate well in terms of rank order and absolute potency to those measured by fluorescent, LC/MS, LC/UV, and radiometric methods. Correlations are closest when assays are matched in terms of enzyme source, substrate concentration relative to its Km, and linearity with respect to time-dependent product accumulation and CYP concentration. In some cases the correlations can be rationalized in light of structural similarities between luminogenic and conventional probe substrates. Likewise, luminogenic cell-based assays detect fold increases in CYP enzyme activities that correlate well to measurements made using conventional assays. The close correlations suggest the value of the luminogenic approach for predicting in vivo effects is at least comparable to the conventional methods. 
James Cali is a Senior Scientist at Promega Corporation where he serves as Group Leader for developing products for drug discovery and drug profiling. The group focuses on bioluminescence approaches to configure novel tools for in vitro high
Advancements in Label-Free Inhibitor Screening via Matrix-Assisted Laser Desorption Ionization-Mass Spectrometry (MALDI-MS)
Kenneth Greis University of Cincinnati, USA Over the past 20 years, mass spectrometry (MS) has often been used to measure enzyme activity and kinetics.
1 However, for rapid screening of inhibitory compounds, fluorescent and chemi-luminescent assays have dominated the market. As the sensitivity and speed of MS have advanced, new opportunities to couple MS with screening applications have come to the forefront. Matrix-assisted laser desorption ionization-MS (MALDI-MS) offers a label-free and direct readout of substrate and product and a fast sampling rate, and is tolerant of many buffer salts, reagents, and compounds that are typically found in enzyme reaction mixtures. Previous studies in our laboratory have demonstrated the utility of a MALDI-MS-based readout for inhibitor screening assays.
2 However, the maximum speed of these analyses was limited to about one sample analyzed every 5-6 seconds. In this report, we exploit the continuous ionization and desorption features of a MALDI-triple quadrupole instrument to improve the speed of analysis to about two to three samples per second while maintaining acceptable CVs (under 12%) for inhibitor screening applications. Furthermore, data demonstrating enzyme activity and IC50 values that are comparable to those obtained from full scan data are presented. Finally some preliminary data are presented to demonstrate the feasibility of using a MALDI-based readout to evaluate multiple target enzymes simultaneously thus opening the door to screening for hits from multiple targets with one pass through a compound repository. 
In this role, he is responsible for developing and applying advanced proteomics technologies both as core resources and as a co-investigator on various projects. He also leads a centralized effort across the GRI, the University of Cincinnati, College of Medicine, and the Cincinnati Children's Hospital Medical Center as the Director of Proteomics. Greis's unique experience in biochemistry, biological mass spectrometry, proteomics, and management of research projects has resulted in his serving on governmental advisory committees for program project and site visits for the US Departments of Energy and Defense. Finally, Greis has developed and published a novel MALDI-mass spectrometrybased compound screening approach as a label-free alternative to tradition high-throughput screening assays and thus he continues to focus research efforts in this developing field.
Assessment of Drug-Lipid Complex Formation by a HighThroughput Langmuir-Balance and Correlation to Phospholipidosis
Juha-Matti Alakoskela Helsinki Biophysics and Biomembrane Group, Finland
Phospholipidosis, the accumulation of phospholipids in cells, is a relatively frequent side effect of cationic amphiphilic drugs. In response to industry need, several methods have been recently published for the prediction of the phospholipidosis-inducing potential of drug candidates. We describe here a high-throughput physico-chemical approach that is based on the measurement of drug-phospholipid complex formation observed by their effect on the critical micelle concentration (CMC) of a short-chain acidic phospholipid. Comparison of results for 53 drugs to data from human data, animal testing, cell culture assays, and other screening methods reveals very good correlation to their phospholipidosisinducing potential. 
Juha-Matti Alakoskela
Challenges and Strategies in Making Effective Use of Early ADMET Data
Philip Burton ADMETRx, Inc., USA
The use of in vitro ADMET data (e.g., measurements of solubility, metabolic stability, CYP DDI, etc.) in making decisions about candidate advancement is universally practiced in modern drug discovery. More recently, given their growing recognition as determinants of pharmacokinetic properties and potential for drug-drug interactions, a growing number of HTS drug transporter assays have been added to the ADMET repertoire. For drug discovery scientists, a practical consequence of this growing arsenal of ADMET assays is an overwhelming accumulation of data where the integration of additional drug transporter assay information represents an even greater challenge to our ability to effectively make decisions about compound advancement. One mechanism is to incorporate ADMET property measurements in a "filtering" mode. Such strategies may be useful in specific applications where a given property, such as drug transport, for example, is so important that it can overwhelm other considerations in deciding to take a drug candidate forward. On the other hand, implementation of hard filters in the drug selection process does not allow for the favorable compensatory interrelationships between many biopharmaceutical properties and may result in elimination of drug candidates that may in fact be well behaved if taken into clinical development. An alternative method for integrating a variety of preclinical profiling data into a decision-making format is the use of Multi-Criteria Decision Making models. This presentation will discuss recent advances in drug transporter assays development and different decision-making strategies available to use this information to positively impact the success of a drug-discovery program. 
Philip Burton is currently Chief
Application of Label-Free Detection to High-Throughput Screening Using Live Cells Expressing Endogenous G-Protein-Coupled Receptors
Magalie Rocheville GlaxoSmithKline, UK G-protein-coupled receptors (GPCRs) have long been regarded as tractable targets for the discovery of drugs and are linked to a plethora of disease indications. Most screening assay formats for GPCRs have traditionally relied on high receptor expression levels and/or the monitoring of distinct signaling routes, all of which may not reflect in vivo tissue efficacy. The emergence of label-free detection methodologies has offered a new insight into monitoring cellular activation in a more holistic fashion. Of note, the ability to probe for endogenous receptor function in native settings is very powerful and may provide more biologically relevant data facilitating hit identification and characterization. We embarked on a study in collaboration with Corning to assess the suitability of the Epic ® system in supporting single shot screening for endogenous cellular responses. Epic uses an optical biosensor to measure the dynamic mass redistribution (DMR) of cellular contents in live cells and signals are temporally resolved following compound stimulation. 1 We first selected human carcinoma A431 cells reported to display b2AR-mediated functional activity 2 and performed validation runs on two separate test occasions using a diverse set comprising ~10,000 low-molecular-weight compounds. End-point reads were captured in dual-assay formats, agonist alone as well as antagonist inhibition in the presence of epinephrine. We then extended the study by probing human osteosarcoma U20S cells with the aim to tackle temporal resolution on DMR responses for a diverse set of ~1,000 compounds tested on two separate days. We tested U20S cells in agonist mode using histamine as control, which is known to elicit Gaq-coupled responses. In this presentation, we will share our findings with respect to assay performance, day-day reproducibility, correlation with other assays, and apparent hit rate. We will share key learnings gained, such as the pros/cons of temporal vs. end-point analysis methods and follow-up on actives in alternative readouts. It is hoped that this study will bring additional data to support the use of phenotypic assays of improved physiological relevance for drug discovery. We describe data from cell-based (parental and primary, adherent and nonadherent) assays of pharmaceutically relevant targets using a novel high-resolution label-free microplate-based technology. High-content screening has provided significant benefit to pharmaceutical scientists working to understand cell function and the effects of pharmaceutical test compounds. The current state of the art relies upon the use of labels, transformed/transfected cell lines, and methods such as light microscopy, which may represent unnatural conditions and may preclude the study of live cells. The novel tool of microplate-based label-free biosensors has begun to show very promising results for cellbased applications (especially G-protein coupled receptors) in a high-throughput screening mode, with little information at the single cell level. The presentation described here will provide data that addresses some of the limitations of current HCS. To date, label-free biosensors have required >20,000 cells/384 well and offered minimal information about cell responses to compound additions, especially at the single cell and small cell cluster level. This presentation aims to show high-resolution (4-80 micron) label-free cell data, based upon high-density (>384+) microplate format sensors. Label-free data will be presented for parental and primary cell lines with detail of focal adhesion, and other cell adhesion properties, chemotaxis, cell migration, neuronal cell growth, and cell interaction with ECM all at <300 cells/well. High-resolution label-free cell response to compound treatment for intracellular targets could all be measured. Data will be presented that demonstrate feasibility of these applications without labels in real time with live cells and over the course of many days. Drug discovery efforts utilize assays covering a range of formats, from initial in vitro screens through in vivo and ex vivo studies. Label-free techniques are currently preferred as they enable rapid assay development. The detection of a given analyte in biological assays often involves development of multiple methods, each tailored to the specific challenges of the assay format. High-Throughput-Mass Spectrometry (HTMS) is an emerging format for high-throughput screening. Whereas mass spectrometry permits direct detection of analytes without need for derivitization, labeling, or capture technologies, a coupled separation step is needed to achieve desalting from biological media. Liquid chromatography (LC) has been the preferred separation technique but is somewhat slow, even under UltraPerformance LC® conditions. Label-free LCMS methods offer the advantage of a single analytical tool applicable to a wide range of biological matrices. This broad applicability opens the possibility of using LCMS as a universal quantitative method for a given analyte in a range of assay formats. We used a modification of this approach wherein the separation component LC is replaced by the RapidFire™ high-throughput solid phase extraction (SPE) sampling system. This was successfully implemented for development of an assay involving a dipeptide of interest. 
Lance G. Laing received his PhD from Johns Hopkins University
Tom Holt carried out his PhD studies in organic chemistry at the University of Illinois in Champaign-
SESSION X
Chemokine Receptor Antagonists: Progress and Lessons Learned
Ronald Gladue-Plenary Speaker Pfizer, USA Leukocyte infiltration into inflammatory sites is believed to be regulated by 8-10 kDa proteins known as chemokines. These chemokines are divided into four groups depending on the spacing between two N-terminal cysteine residues, and interact with 7TM GPCRs. The therapeutic potential for inhibiting chemokines or their receptors is supported by their enhanced expression in human disease, numerous studies in animal models, and, in some instances, genetic association studies. These reports have prompted the identification and characterization of a number of chemokine receptor antagonists, several of which have entered clinical trials. In this talk, I will highlight the progress made in identifying chemokine receptor antagonists for inflammatory diseases, the rationale for bringing these into clinic, and lessons learned from clinical trials.
Therapeutics: S1P Receptors Under the Influence
David Marsolais
The Scripps Research Institute, USA Therapeutic potential of sphingosine analogs was confirmed for allograft rejections and autoimmune diseases, where immunosuppression is caused by sequestration of lymphocytes in the secondary lymphoid organs following in vivo phosphorylation of the synthetic sphingosine analog, and activation of the sphingosine-1-phosphate receptor 1 (S1P1). Five high-affinity receptors, although, exist for sphingosine-1-phosphate (S1P1 to S1P5). Those widely and differentially distributed receptors emerge as major immunological and homeostatic regulators, with precise functions associated with each receptor. Resolving the contribution of distinct S1P receptors in a tissue-specific manner therefore constitutes an essential step for development of low side effect chemical amelioration of immunological diseases. Our approach combines the use of genetic knockdowns and newly developed specific agonists and antagonists of the S1P receptors. Evidence for therapeutic usefulness of chemical modulators of S1P receptors will be presented in models of inflammation and viral infections. 
David Marsolais completed his doctoral degree at Laval
CCR2 in Monocyte Trafficking and Early Atherosclerosis
Israel Charo Gladstone/UCSF, USA Monocytes are the precursors of the lipid-laden macrophages in atherosclerotic fatty streak lesions. Recent work has identified the chemokines as critically important recruiting signals for the migration of monocytes from the blood to the developing atherosclerotic lesions in the vessel wall. CCR2 is highly expressed on inflammatory monocytes, and contributes to their egress from the bone marrow as well as to their recruitment to sites of inflammation. Of the chemokine receptors expressed on monocytes, evidence has emerged for important roles for CCR2 and CX3CR1 in atherogenesis. During this talk I will review these findings, and I will present new data demonstrating expression of CCR2 on hematopoietic stem cells. Finally, I will summarize the results of recent clinical trials involving CCR2 and other chemokine receptor antagonists.
Israel Charo is a Senior Investigator at the Gladstone Institutes in San Francisco. He was the first to clone CCR2 and to demonstrate its role in monocyte chemotaxis and atherosclerosis. Prior to this
Charo studied the role of GPIIb-IIIa in platelet aggregation and was one of the scientific founders of COR Therapeutics, which developed Integrilin.
CCX282-B: First In Class Oral CCR9 Antagonist for the Treatment of Inflammatory Disorders of the Bowel
Juan Jaen ChemoCentryx, USA CCR9 is a chemokine receptor that plays a pivotal role in mediating the migration of T cells to the mucosal surface of the gut. CCL25/TECK, the ligand for CCR9, is highly expressed in intestine and blockade of this interaction with antibodies to ligand or receptor is known to impair migration of T cells to the gut. The pathogenicity of intestinal CCR9+/CD4+ T cells is implied by their substantial increase in the circulation of patients with Crohn's or Celiac Disease. Pharmacological inhibition of CCR9 offers a novel and selective approach to the treatment of inflammatory disorders of the bowel. Pharmacological inhibition of CCR9 offers a novel and selective approach to the treatment of inflammatory disorders of the bowel. We have discovered CCX282-B, an orally bioavailable, highly selective and potent small molecule antagonist of CCR9. The compound is equipotent against the human and murine receptors and is highly efficacious in preclinical disease Oral Abstracts models. Both prophylactic and therapeutic use of CCX282-B resulted in a significant improvement in MDR1a-/-mice, a model of colitis. Treatment of TNF-DARE mice with CCX282-B resulted in a significant decrease in the intense intestinal inflammatory infiltrate observed in this ileitis model. In Phase I clinical studies, CCX282-B was well tolerated. In a recently completed 28-day placebo-controlled Phase II study in patients with moderate to severe Crohn's disease, designed to test safety and tolerability in a patient population, CCX282-B was shown to be safe and well tolerated. Furthermore, dosing with CCX282-B resulted in encouraging clinical results. 56% of patients on CCX282-B (CDAI = 250, CRP > 7.5 mg/L) exhibited a 70-point drop in CDAI compared to 29% on placebo. Analysis of CRP plasma levels showed a decrease of 11 mg/L in the CCX282-B group compared to placebo. A large multinational Phase II/III study (PROTECT-1) is currently evaluating the ability of CCX282-B to induce and maintain a treatment response in Crohn's patients.
SESSION XI
Fragments in Structure-Guided Drug Discovery
John Barker-Plenary Speaker Evotec, Ltd., UK Structure-guided lead optimization is an integral component of many drug-discovery programs. Recent advances in structural techniques have allowed crystallography to be initiated earlier in the drug-discovery cascade with the question "Can we get a crystal structure" increasingly becoming a pivotal decision point in the prioritization of programs to advance. The topic of this presentation will be the use of structural data in lead optimization. The talk will exemplify the use of structural information in the area of fragment-based drug discovery. The identification of hits through both NMR and bioassay-based screens and the subsequent determination of binding mode (or modes) of active fragments by high-quality x-ray crystallography will be discussed. With structure as a guide, rapid increases in potency and selectivity can be delivered in parallel with optimization of drug likeness properties. The use of structure in lead optimization will be highlighted with case studies including Heat Shock Protein 90 and Hematopoietic Prostaglandin D2 Synthase. 
John Barker is the Group Leader of the Structural Biology team at Evotec based at Evotec
Exploratory Directions in Multi-Structure Data Mining: The Optimization of Potent HIV-RT Nonnucleoside Inhibitors
Seth Harris Roche Palo Alto, USA Successful high-throughput structural biology in support of drug discovery requires efficient data tracking. We have developed and implemented a PHP/MySQL relational database system to chart our structure determinations. This has enabled a dramatic increase in our throughput with a direct impact on our structure-based screening methodologies, but in turn challenging the traditional tools of protein structure analysis. We explore the opportunities to parameterize threedimensional structures and thereby apply statistical methods to cluster and compare binding modes, protein features, and ligand characteristics. The challenge is to determine whether correlations can be discovered that elucidate relevant structural motifs not evident in examination of a single or a few structures. As a venue for this discussion, HIV reverse transcriptase provides a particularly challenging case study, presenting a highly flexible and mutable induced binding site. Next-generation nonnucleoside reverse transcriptase inhibitors will have to be potent across a broad range of mutant enzyme sequences, not simply the wild type protein. Properties such as a flat mutant profile can be quite subtle from a structural standpoint. The overview of our crystallography group's workflow in the context of lead discovery and optimization highlights the integration of data tracking tools and structure determination, focusing on structural themes and landmarks in our development of potent nonnucleoside inhibitors of HIV reverse transcriptase. structure-function maps can require months to years to map even small portions of a protein's topography. We have developed a novel strategy, Shotgun Mutagenesis, for rapidly and inexpensively deriving detailed maps of the binding sites of drugs, antibodies, and other ligands. Shotgun Mutagenesis involves altering every amino acid in a target protein to test which residues are required for an interaction of interest. In our studies with the chemokine receptor CCR5, a GPCR, we used Shotgun Mutagenesis and cell-based functional assays to rapidly identify the binding sites for diverse ligands, including a small molecule drug candidate, monoclonal antibodies, HIV virus envelopes, and chemokine ligands. The contact residues identified for the small molecule TAK-779 were used as constraints to guide the computational docking of the drug with a structural model of CCR5. The energy-minimized binding configuration provided a three-dimensional model of the most plausible drug-target interaction for further lead optimization. As part of our studies, the binding epitopes for two MAbs, 45523 and 2D7, were also mapped along the entire length of the CCR5 molecule. One amino acid in CCR5, E172, appeared critical for receptor recognition by both antibodies. To investigate the detailed structural contribution made by this residue, we mutated E172 to all other possible amino acids and tested each mutant for antibody binding. By testing for acceptable and nonacceptable side-chains at residue 172, we concluded that 2D7 was interacting with the carbonyl structure of E172, while 45523 was interacting with the carboxylate structure of E172. Shotgun Mutagenesis thus made it possible to formulate atomic-level structural hypotheses about how specific residues contribute to receptor interactions. To the best of our knowledge, our results are the most comprehensive structure-activity analyses of any GPCR ever reported. We expect that this strategy will be useful for visualizing the precise binding sites of drugs, antibodies, and ligands to facilitate lead optimization with difficult protein targets. 
Cheryl Paes leads the production and development of the
SESSION XII
Is There a General Model for Bioactivity? An Overview of the MLSMR-MLSCN Bioassays
Tudor I. Oprea-Plenary Speaker University of New Mexico, USA The Molecular Libraries Screening Centers Network (MLSCN) uploads bioactivity screening data in PubChem (http://pubchem .ncbi.nlm.nih.gov/) based on the Molecular Libraries Small Molecules Repository (MLSMR). On 10-29-2007, we found 142,416 unique MLSMR compounds tested on 317 MLSCN bioassays. Not all compounds were tested on all assays. By number of assays, the compounds are distributed as follows: 30.9% on 11-20 assays, 16.2% on 41-50 assays, 12.6% on 61-70, 5% on 111-120, 26.75% on 121-130, and 5.2% on 131-140 assays, respectively, on 110,161 compounds. The majority of MLSMR compounds are "inactive" in the above numbers of assays. A smaller subset of MLSMR were active (35.9%, active in > one assay), or among inconclusives (38.46%, in > one assay). Overall, a large percentage of compounds are inactive in all assays to date. This dataset allows us to address the following question: Is there a general model for bioactivity? We used chemical fingerprints (560 predefined keys) and a machine learning technique (support vector machines, SVM) to discriminate actives from inactives. For "inactives" we used compounds that were found inactive in at least 60 assays; all actives or inconclusives were removed from this dataset, to yield over 20,000 compounds. From a pool of 3000 actives and 20,000 inactives, a set of 300 randomly selected compounds were used to build 100 different active/inactive models using a Radial Basis Function SVM kernel. External prediction yields >70% accuracy in both the active class (1888 out of 2663 actives) and the inactive class (15776 out of 20223 compounds). Analyses based on estimated aqueous solubility, octanol/water portioning, and molecular weight do not indicate significant differences between actives and inactives. Furthermore, a large number of chemical scaffolds are present in both the active and inactive class. Artifactual results, such as fluorescent compounds, and aggregators, were not individually examined. However, in one MLSMR/MLSCN assay, only ~1100 compounds out of ~70,000 were considered potential aggregators. Taken together, these results appear to indicate that bioactivity, as captured in the MLSMR/MLSCN "active" class, can be discriminated from the "inactive" class from the same dataset. If validated by additional data, such models could be used to enrich screening libraries with compounds that are more likely to belong to the "active" class. Medicine and Pharmacy, in Timisoara, Romania. Past appointments include Washington University in St. Louis and Los Alamos National Laboratory. Between 1996 and 2002 The design of an "ideal" screening library is highly dependent on the biological question one is posing. Is the biological target considered tractable or difficult with respect to small-molecule ligands? Is it a member of a well-characterized superfamily or not? If so, screening libraries designed to focus on the superfamily have often proved to be a highly successful route to new clinical candidates when compared with the screening of traditional "diverse" libraries. Indeed, such focused libraries can even be designed to provide initial SAR to facilitate key decisions about which hit series to follow up. This presentation will seek to summarize and compare current and future approaches to focused library design, covering ligand-based and sequencebased as well as target structure-based paradigms. These will be illustrated with examples from published work and from our own studies on protein kinases and ion channels, highlighting particularly the experimental evidence of the success, limitations, and weaknesses of these approaches with respect to diversity-screening alternatives. Encoded Library Technology (ELT) is a new approach to lead discovery based upon the creation of large encoded libraries of novel, drug-like structures that can be rapidly screened to identify families of compounds with affinity for a macromolecular target. The utility of libraries assembled by combinatorial chemistry to molecular discovery has been constrained due to deconvolution limitations: ELT addresses this issue by encoding each molecule with a covalently attached DNA sequence. The resulting libraries are screened by "selection" on the basis of affinity, "hits" identified by highcapacity DNA sequencing, and the corresponding organic structures synthesized without the DNA tag and tested in biochemical assays. ELT Libraries are constructed by sequential "split and pool" cycles that alternate organic synthesis with enzymatic oligonucleotide ligation: in this way we have been able to assemble a library pool containing over 10 billion (10^10) structures. We will describe studies with these libraries against a variety of protein targets, yielding families of "hit" molecules that inhibit the function of these targets with single-digit nanomolar potency.
Tudor I. Oprea holds an MD and a PhD from the University of
John Harris
by organizing and clustering large numbers of chemical substances. A practical application of this technology will be provided in the form of a case study examining a recently identified methionine aminopeptidase enzyme. An inhibitor of this enzyme has been identified using high-throughput screening. Additional commercially available candidates will be identified using the substance clustering and visualization methods recently developed by CAS. Having the right information is crucial for modeling building, conducting robust data analyses, and constructing useful workflows and decision support systems. Exploring "how much" and "what" information is worthy of codifying and archiving is always a dilemma. Examples from molecular modeling contributions to drug discovery will illustrate how earlier strategies for codifying date have paid off, and since knowledge management always has a cost, the frustration of implementing information strategies for the future. ChemSpider is an online database of over 20 million chemical structures assembled from almost a hundred data sources including chemical and screening library vendors, publicly accessible databases and resources, commercial databases, and open access literature articles. Such a public resource provides a rich source of ligands for the purpose of virtual screening experiments. These can take many forms. This work will present results from two specific types of studies: 1) Quantitative Structure Activity Relationship (QSAR)-based analyses and 2) In-silico docking into protein receptor sites. We will review results from the application of both approaches to a number of specific examples using the software outlined below. The QSAR analyses utilize the ChemModLab environment, which is a free, web-based toolbox for fitting and assessing quantitative structure-activity relationships. Its elements include a cheminformatics front end to supply molecular descriptors, a set of statistical methods for fitting models, and methods for validating the resulting model. Five molecular descriptor sets are used with 16 math-modeling methods to give a total of 80 QSAR models. The input is a file of compounds and a text file for biological activity. The in-silico docking experiments are conducted using a combination QSAR/Docking approach using the SimBioSys eHITS and Lasso software programs. The docking procedure allows for the screening of a complete molecular database to obtain the correct binding poses and estimated binding affinities. The ligand-based screening tool utilizes a novel conformation-independent 3D QSAR descriptor, ideally suited for scaffold hopping. 
Antony Williams is the President of ChemZoo
Predictive QSAR Modeling of Biological Screening Data
Alexander Tropsha University of North Carolina at Chapel Hill, USA We shall discuss the application of quantitative cheminformatics approaches (such as Quantitative Structure Activity Relationship Modeling, or QSAR) to the analysis of biological screening data. Specifically, I will concentrate on QSAR modeling workflow that affords robust and validated models capable of accurate prediction of compound properties for molecules not included in the training sets. Such models can be used to screen virtual databases of existing or synthetically feasible compounds and annotate these compounds with highly reliable predicted properties. I will present examples of studies demonstrating that in several cases of blind prediction (metabolic stability, genotoxicity, protein binding, anticonvulsants) we have achieved the experimentally validated external prediction accuracy of at least 80%; excluding compounds outside the model applicability domain helped increase accuracy by at least 10%. We will present the results of our recent studies of screening datasets deposited in the PubChem by the NIH-funded Molecular Libraries Screening Center Network and the use of these models (i.e., predictors) to prioritize the selection of compounds for subsequent screening. We shall emphasize that focus on bioactivity forecasting brings QSAR modeling forward as predictive, as opposed to purely evaluative scientific discipline. We suggest that cheminformatics approaches continue to emerge as important decision support tools for the experimental medicinal chemistry. 
Alexander Tropsha is professor and chair in the Division
Practical Methodologies for Hit Identification in High-Throughput Screening Data
Tongying Shun University of Pittsburgh, USA High-throughput screening (HTS) has played a dominant role in drug discovery over the past decade. The goal of HTS is to identify active compounds (hits) by screening large numbers of diversified chemical compounds against selected targets and/or cellular phenotypes. The HTS process consists of multiple steps involving compound handling, liquid transfers, and assay signal capture, all of which unavoidably contribute to systematic variation in the screening data. The challenge is to distinguish biologically active compounds from systematic assay variability. Traditional controlbased and non-control-based statistical methods have been widely used for HTS hit identification by both the pharmaceutical industry and academic sectors. More recently, improved statistical methods, such as the B scores method, have been introduced. To apply such robust methods most effectively, we have to understand their necessity and functionality. Several examples are presented to illustrate that robust statistical methods may sometimes be misleading and can result in more rather than less false negatives. In practice, there is no single method that is the best hit detection method for every HTS data set. Rather, we have developed statistical decision methodologies to determine which hit identification method should best be applied to each HTS campaign. In the few last years there has been considerable advancement in automatic planar patch-clamp technologies. These developments have made it feasible to increase the throughput of electrophysiological recordings of ion channels several fold. As a consequence, ion channel recordings with these platforms now produce a large amount of data that need to be analyzed. The onslaught of massive amounts of data was also experienced when the microarray technology was developed and that later resulted in a strong emphasis on developing adequate data analysis methods for such data. Likewise, when planar patch-clamp platforms are used for ion channel profiling activities, new strategies and methods need to be developed that can QC large amounts of electrophysiological recording traces. We have developed a strategy using modular Matlab applications to organize the flow of electrophysiological data from QPatch and IonWorks Quattro into reliable potency assessments. Principally, our strategy is to pass the data through several layers of preset quality control filters. Initially, criteria from the raw data trace of the individual recordings are examined. Next, we evaluate pharmacological properties of each recording for a compound, and finally the quality of the fit for the IC50 determination is inspected. All the parameters in the different filters are recorded, thereby ensuring integrity, consistency, and transparency of data and their analysis before reporting it to end users as well as to corporate databases. 
Mats Holmqvist is currently a Labhead at Novartis
SESSION XIV
Ubiquitous siRNA Delivery by Peptide Transduction-dsRNA Binding Domain Fusions
Steven F. Dowdy HHMI-UCSD, USA Intracellular molecules, especially non-kinase and non-enzymatic molecules, are inherently difficult targets to develop traditional small molecule therapeutics toward and are essentially therapeutic orphan targets. However, selective mRNA degradation by siRNA-induced RNA interference (RNAi) opens an avenue to specifically go after these orphan targets, as well as previously drugged targets, and thereby has great potential to treat human disease, especially cancer with its myriad of genetic alterations. Unfortunately, due to their size (~14,000 Dalton) and extensive anionic charge, siRNAs have no bioavailability to enter unperturbed cells. Current siRNA delivery approaches fail to deliver siRNAs into a high percentage of cells in a non-cytotoxic fashion, especially primary cells. Here we developed a Peptide Transduction Domain-dsRNA Binding Domain (PTD-DRBD) fusion protein siRNA delivery approach. DRBDs bind siRNAs with high avidity independent of sequence, mask the negative charge, and allow for PTD-mediated siRNA delivery. PTD-DRBD-delivered siRNAs induced RNAi responses in the entire cell population of 18 cell types assayed in a non-cytotoxic fashion, including fibroblasts, keratinocytes, neuronal cells, hematopoietic lineages, and human embryonic stem cells. PTD-DRBD-mediated intranasal siRNA delivery resulted in efficient gene knockdown in mouse models in vivo. Moreover, PTD-DRBD-delivered EGFRvIII siRNAs resulted in EGF-Receptor knockdown in intracerebral glioblastoma tumors in vivo with significant increases in longevity. Taken together, these observations demonstrate a ubiquitous siRNA delivery approach by PTD-DRBD fusions. Proteases are one of the largest enzyme families encoded by the human genome with more than 500 active members identified to date. Despite the fact that proteases have historically been proven as a valid target class for drug discovery and development, various members of this target family still comprise a significant challenge for modern drug discovery. In this presentation we will outline the benefits and limitations of the various lead-finding technologies applied for drug discovery on proteases. We will describe the fundamental strategy and the experimental setup for high-throughput screening, compound profiling, and lead optimization on proteases with various examples from research projects performed at the Novartis Center of Proteomic Chemistry. We will demonstrate that close intertwinement of high-throughput screening, compound profiling, structural biology, and medicinal chemistry and the application of state-of-the-art readout technologies (such fluorescence lifetime in HTS, label-free detection methods for hit validation, and hit follow-up), powerful data capturing, and analysis tools, as well as a process-driven organizational structure are the key success factors for drug discovery on that challenging target family. 
Lorenz Mayr
Allosteric Modulators at G-Protein Coupled Receptors: A Means of Increasing the Tractability of Intractable GPCRs
Stephen Brough GlaxoSmithKline, UK
The past decade has seen the identification of a multitude of allosteric modulators of G protein-coupled receptors (GPCRs). These ligands interact with binding sites topographically distinct from the orthosteric ligand to enhance the activity of the natural agonist. This observation has led to considerable excitement in the industry. Drug screening programs are routinely being configured to identify both orthosteric and allosteric ligands to increase the likelihood of identifying multiple start points for chemistry. Furthermore, screening for allosteric modulators is particularly attractive at receptors for which classical agonist screening campaigns have been unsuccessful. This presentation will review activities within GSK and elsewhere to identify such ligands at family A, B, and C GPCRs. We will describe how advances in reagent generation and screening technologies have enabled the development of both HTS and subsequent SAR assays to identify and characterize allosteric modulators and will describe how we have addressed the challenges encountered in this work. We will review the outcome of these projects and describe the issues to be addressed in taking allosteric modulators toward the clinic. Glasgow, Scotland, in 1995 
Stephen Brough received an Honours Degree in Biochemistry from The University of
Mapping Biochemical Pathways in Human Disease by Integrated Proteomics and Metabolomics
Benjamin Cravatt
The Scripps Research Institute, USA Breakthroughs in the diagnosis and treatment of cancer depend on the discovery of new biomarkers and therapeutic targets for this disease. Toward this end, global molecular profiling methods hold great promise, as they provide a relatively unbiased portrait of the biochemical composition of cancer cells and can reveal unanticipated alterations in their metabolic and signaling networks. Nonetheless, the identification and functional characterization of enzymatic pathways that support cancer pathogenesis have, to date, been hindered by a lack of "systems biology" techniques that can evaluate their activity in complex biological samples. Given the bevy of chemically intractable effector genes and challenging targets in cancer, an approach focused on discovering critical biochemical pathways and enzymatic targets in cancer would be beneficial. To address this, we have introduced functional proteomic and metabolomic technologies termed activity-based protein profiling (ABPP) and discovery metabolite profiling (DMP), respectively. ABPP, which utilizes active site-directed chemical probes to determine the functional state of large numbers of enzymes directly in whole proteomes, has enabled the discovery of enzyme activities that are elevated in aggressive cancer cells and tumors. DMP, which constitutes a global, untargeted method to characterize metabolic fluxes, has facilitated the discovery of natural substrates for known and novel cancer-related enzymes. In this presentation, I will discuss our group's progress toward uniting the ABPP and DMP methods to an integrated platform for the global analysis of biochemical pathways altered in human cancer cells. Specifically, I will discuss: 1) the identification of enzyme activities and lipid metabolites that are elevated in aggressive cancer cells, and 2) the integration of these enzymes and small molecules into networks and our efforts to test the function of these biochemical pathways in cancer pathogenesis. These approaches applied broadly across disease states bias systems-wide scans toward enzymatic effectors and the discovery of chemically tractable targets.
SESSION XV
Freedom of Expression: High-Throughput Protein Production
Stephen Chambers-Plenary Speaker Vertex Pharmaceuticals, USA The pressure to supply proteins in a timely and efficient manner for drug discovery has brought about dramatic changes in the way these reagents are now being produced. Technological advancements in both automation and micro fluidics when applied to expression, purification, and analysis have altered beyond recognition how proteins are being made for research. In this new era of protein production, with variability minimized using statistical design of experiments, proteins are rapidly becoming a readily available commodity capable of being made in a highly industrialized fashion. The traditional end users of proteins in assay development and high-throughput screening are the most obvious to gain from the changes in availability. Other protein-hungry users in structural biology have also been able to exploit the increased throughput in expression for their own ends. Also poised to benefit are newer technologies that have been thwarted by the lack of protein content for devices, such as protein and antibody arrays. Despite the potential high-throughput protein expression it offers, its application is still viewed skeptically by some purists, who argue that the complexity of protein production cannot be successfully operated as an automated process. Application of highthroughput expression in the production of a number of different proteins and families will be presented, including data on a number of recalcitrant proteins reliant on high-throughput expression, in conjunction with design of experiments, for successful production. How many times have you found yourself thinking that as you review your goals? Just like every other discipline in the pharmaceutical industry, reagent provision groups face the everincreasing pressure to deliver "more for less." The development and bulk provision of biological reagents has always been a critical component of small molecule drug discovery. To intensify the demands made of such reagent supply teams, the increased prevalence of biological therapeutics and vaccines within mainstream pharmaceutical industry has led to even greater numbers of projects to support, without growing headcount. In response to such pressure, reagent provision groups have evolved by utilizing automation (i.e., high-throughput strategies) and exploiting both scientific (e.g., frozen cells) and business practices (e.g., process improvement, outsourcing) to increase the quality and flexibility of reagent supply. The diversity of site-based practices within Pfizer Discovery will be used to illustrate paradigms for complementing the application of your internal expertise with those of contract research organizations. Whether working as part of a large global organization or a smaller biotech company, there clearly is not a single solution that fits all those that keep drugs being discovered. 
Stephen Chambers is co-founder and VP of Protein Production
Simon Eaglestone
Three Dimensional Cell Culture and Laboratory Automation: From Freezer to Assay in One Step
Robin Felder University of Virginia, USA Background: Three-dimensional cell culture is demonstrating increased relevant data for drug discovery, regenerative medicine, and basic research. However, this relatively new paradigm has several technical challenges including the need for automation, streamlining the time from cryopreserved state to assay, and batchto-batch consistency. Methods: We developed an automated platform that would allow rapid cell-based analysis using frozen cells on a 3D platform. Cells cryopreserved on a 3D substrate were tested using G protein coupled receptor assays and measurement of cell viability and morphology. Results: Cells were cultured to high density and cryopreserved on the 3D substrate. We demonstrate an increase in cell survival, 83 ± 3.2 for plastic versus 92 ± 2 on microcarriers. Cells were then assayed for response in a biochemical assay and those cryopreserved on microcarriers gave a robust response. Additionally, we demonstrate using cells as reagents that we can decrease the labor output needed while also decreasing the intra-and inter-assay variability. Lastly, 3D cell culture reduced hypoxia in human primary proximal tubule cells as measured by caveolin expression (plastic 18,852 ± 2508 RFU indicating hypoxia; 2818 ± 1105 RFU on our 3D substrate, P < 0.05, n = 6). Conclusion: 3D culture on microcarriers results in decreased labor invested in cell culture and improved biochemical response as compared to conventional culture on plastic. This process can be automated to reduce cell handling from freezer to assay while also decreasing the variability usually associated with conventional cell culture. Our findings and their implications for using cells as reagents will be discussed. 
As a University Professor and Director of the Medical Automation
Strategies to Address the Challenges of Delivering High Quality Recombinant and Primary Cell Lines for uHTS
Alison Rush Merck & Co. Inc., USA Cell-based assays play an increasingly predominant role in screening strategies as we strive to develop biologically relevant assays. Successful ultra high-throughput screening (uHTS) campaigns require high-quality cell production in quantities that are challenging for both automated and manual cell culture techniques. The Department of Automated Biotechnology has centralized cell culture activities to support the core screening facility. This team provides cells during all stages of the screening process, including assay development for small molecule and target identification screens through scale-up for uHTS. In combination with traditional cell culture protocols, we employ a variety of approaches to providing high-quality cells in quantity. Both automated and manual cell culture are used to meet the demands for cell supply, and the rationale for distribution between these resources is discussed. In addition, we have implemented two novel high-density cell culture technologies to more efficiently meet the growing demands of cell-based assays. The optimization, validation, and implementation of these methods will be presented. However, recombinant cell lines that overexpress a target of interest are increasingly viewed as artificial systems that may not reflect appropriate target biology. As a result, primary cell lines, or cell lines with endogenous expression profiles, are becoming more prevalent in
